Robert Alter, MD, John Theurer Cancer Center

Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.

Novel strategies being explored in various stages of clinical trials as potential therapies for relapsed/refractory metastatic renal cell carcinoma.

Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.

An overview of treatment options for previously treated metastatic renal cell carcinoma.

A summary of current therapies and ongoing investigations of adjuvant therapy for patients with operable renal cell carcinoma.

Novel therapies currently being investigated as frontline options for metastatic renal cell carcinoma.

A panel discussion regarding individual preferences for treating favorable-risk metastatic renal cell carcinoma.

Dr Amishi Y. Shah, of MD Anderson Cancer Center, describes the rationale for active surveillance vs treatment with a novel therapeutic in metastatic renal cell carcinoma.

Factors oncologists should consider prior to selecting a novel treatment approach for metastatic renal cell carcinoma.

Variables that impact one’s decision to treat metastatic renal cell carcinoma with an immunotherapy-based regimen that includes a targeted agent vs additional immunotherapy.

Recommendations for dosing targeted therapy-immunotherapy combinations used to treat patients with metastatic renal cell carcinoma.

Characteristics that distinguish the CLEAR trial of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma from other pivotal trials of immunotherapy plus tyrosine kinase inhibitors.

Robert S. Alter, MD, provides key takeaways from the CheckMate 9ER study of nivolumab plus cabozantinib as frontline therapy for patients with metastatic renal cell carcinoma.

Thomas Powles, MD, MBBS, MRCP, describes the KEYNOTE-426 trial in frontline metastatic renal cell carcinoma and comments on the use of pembrolizumab plus axitinib for appropriate patients.

Amishi Y. Shah, MD, comments on the significance of updated survival data revealed by the CheckMate 214 study using the combination of ipilimumab plus nivolumab as frontline therapy for metastatic renal cell carcinoma.

Dr. Sandy Srinivas comments on treatment approaches for frontline metastatic renal cell carcinoma based on the emergence of novel combination regimens that introduce immunotherapy.

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.

A brief discussion on current second-line treatment options available to patients with metastatic renal cell carcinoma previously treated with a novel-based regimen.

The significance of studying predictive biomarkers to help oncologists identify mechanisms of resistance to immunotherapy agents in metastatic renal cell carcinoma prior to initiating therapy.

An overview of novel-based treatment strategies and biomarkers that are currently under investigation to help address current unknowns when treating patients with metastatic renal cell carcinoma.

Limitations of current data surrounding the appropriate use of immunotherapy plus a tyrosine kinase inhibitor as frontline therapy for patients with metastatic renal cell carcinoma and current recommendations for selecting an appropriate combination regimen.

Based on data demonstrated by the recent CLEAR study in metastatic renal cell carcinoma, oncologists comment on decisions for using lenvatinib plus pembrolizumab vs lenvatinib plus everolimus.

Robert S. Alter, MD, of the John Theurer Cancer Center, highlights key data revealed by the phase 3 CLEAR study in metastatic renal cell carcinoma.

A panel of oncologists discuss the appropriateness for using PD-1 inhibitors versus PD-L1 inhibitors as frontline treatment for metastatic renal cell carcinoma.

Advice for appropriately dosing newer novel-based strategies used to treat metastatic renal cell carcinoma and best practices to help community oncologists avoid drug discontinuations.

Expert oncologists debate the significance of using quality of life as a metric when assessing patients’ responses to therapy for metastatic renal cell carcinoma.

Takeaways of the CheckMate 9ER trial of nivolumab plus cabozantinib vs sunitinib in previously untreated metastatic renal cell carcinoma.

Drs Bradley A. McGregor and David F. McDermott comment on best approaches for selecting and optimizing treatment with novel combination regimens to manage patients with intermediate- or poor-risk metastatic renal cell carcinoma.

Thomas E. Hutson, DO, PharmD, of Texas Oncology, reacts to results demonstrated by the CLEAR study of lenvatinib in combination with pembrolizumab or everolimus for the treatment of metastatic renal cell carcinoma and discusses best practices for educating community oncologists on dosing with lenvatinib.

Considerations for evolving from using single-agent therapy to combination approaches to treat intermediate or poor-risk metastatic renal cell carcinoma based on more recent data demonstrated in clinical trials.